NEWPORT BEACH, Calif.--(BUSINESS WIRE)--ROTH Capital Partners (ROTH), www.roth.com, a full service investment bank focused on serving emerging growth companies and their investors, today announced that it will host its Immuno-Oncology Corporate Access Day on Wednesday, December 16th, 2015 at the Park Hyatt in New York City.
ROTH’s Immuno-Oncology Corporate Access Day will give investors the opportunity to interact with senior management of a select group of Immuno-Oncology companies. There will also be a keynote luncheon with Immuno-Oncology expert Joshua Brody, M.D., Director of the Lymphoma Immunotherapy Program at The Mount Sinai.
The event will allow for extensive interaction and on-on-one meetings with management teams, providing in-depth insights into each company.
ROTH biotechnology senior research analysts Joe Pantginis, Ph.D., Elemer Piros, Ph.D. and Michael Higgins, will be available to discuss their perspectives regarding the companies attending and their views regarding the current biotechnology market trends.
“Immuno-oncology continues to transform cancer therapy and has taken major strides forward over the last couple of years with the approval of the checkpoint inhibitors Opdivo and Keytruda. Engaging the immune system to combat cancer has represented a validated new approach with striking clinical data leading to a new standard of care in multiple indications,” says Joe Pantginis, Ph.D., Senior Biotechnology Research Analyst at ROTH. “These companies are focusing on varying approaches to cancer immunotherapy, including, in part, checkpoint inhibitor approaches, cancer vaccines and direct T-cell therapy. Immune approaches are attracting broad interest from the investment community, physicians and drug companies and we expect this trend to continue as more positive data reads out,” he continues.
“Given the rapid developments and changing dynamics in this sector, our objective of this corporate access day is to provide investors with direct interactions with management teams of a select group of leading Immunotherapy companies,” commented John W. Chambers, Vice Chairman and Head of Healthcare Investment Banking at ROTH. “These companies will be available for 1x1 meetings with investors to present their technology, clinical development strategies, clinical achievements to date and upcoming milestones and catalysts. The event is intended to enable investors to gain direct insight into the key value drivers for this group of innovative companies.”
ROTH has built a leading Healthcare Investment Banking Group over the last several years and has raised approximately $11.8 billion in over 275 Healthcare transactions since 2010. *Past Performance is not indicative of future returns. (Source: ROTH Capital 10/15/2015)
The event is for institutional clients of ROTH and is by invitation only. For more information, please contact your ROTH sales representative at 949-720-5700 or e-mail: conference@roth.com
Wednesday | December 16, 2015
8:00 a.m. - 9:00 a.m. | Registration and Morning Coffee
8:45 a.m. -
9:00 a.m. | Introduction by ROTH Senior Research Analysts
9:00 a.m.
- 4:45 p.m. | 1-on-1 / Small Group Meetings
12:00 p.m. - 1:00 p.m.
| Immuno-Oncology Keynote Luncheon with Dr. Joshua Brody “Two
Solutions to the Limitations of Checkpoint Blockade”
Venue:
Park Hyatt New York
153 West 57th Street
New York City, New
York 10019
646-774-1234
Participating Companies
| The following participating companies are confirmed as of the date of this release: | ||||
| Aduro BioTech, Inc. | ADRO | |||
| Argos Therapeutics, Inc. | ARGS | |||
| Celldex Therapeutics, Inc. | CLDX | |||
| Cellectis S.A. | CLLS | |||
| Galena Biopharma, Inc. | GALE | |||
| ImmunoCellular Therapeutics, Ltd. | IMUC | |||
| Lion Biotechnologies, Inc. | LBIO | |||
| MacroGenics, Inc. | MGNX | |||
| Nektar Therapeutics | NKTR | |||
| Peregrine Pharmaceuticals, Inc. | PPHM | |||
| Pieris Pharmaceuticals, Inc. | PIRS | |||
| TG Therapeutics, Inc. | TGTX | |||
Event sponsors include Business Wire and Ellenoff Grossman & Schole LLP
About ROTH Capital Partners, LLC:
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. and Hong Kong. For more information on ROTH, please visit www.roth.com.
